Stevens Capital Management’s Adverum Biotechnologies ADVM Stock Holding History

Stevens Capital Management’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-1,159	Closed	-$42K	–	797
2017 Q3	$42K	Sell	1,159 -574	-33%	-$15.9K	﹤0.01%	813
2017 Q2	$43K	Buy	1,733 +338	+24%	+$9.24K	﹤0.01%	821
2017 Q1	$38K	Buy	+1,395	New	+$39.7K	﹤0.01%	838
2016 Q3	–	Sell	-1,094	Closed	-$35K	–	881
2016 Q2	$35K	Sell	1,094 -175	-14%	-$7.91K	﹤0.01%	866
2016 Q1	$66K	Buy	+1,269	New	+$70.9K	﹤0.01%	843
2015 Q4	–	Sell	-1,057	Closed	-$87K	–	898
2015 Q3	$87K	Buy	+1,057	New	+$135K	﹤0.01%	906

Other funds holding ADVM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Stevens Capital Management's ADVM Position: Q4 2017 in Review

Stevens Capital Management sold out of Adverum Biotechnologies (ADVM) in Q4 2017, closing a stake of 1,159 shares — an estimated $42K sold.

Stevens Capital Management first reported a position in ADVM in Q3 2015 and held it in 6 quarters. The position peaked at $87K in Q3 2015. 65 funds tracked by Wall St. Rank hold ADVM as of Q4 2017.

Stevens Capital Management reported no remaining Adverum Biotechnologies position as of Q4 2017 after selling out during the quarter.
Stevens Capital Management sold 1,159 Adverum Biotechnologies shares in Q4 2017, an estimated $42K.
Stevens Capital Management first reported a position in Adverum Biotechnologies in Q3 2015 and held it in 6 quarters.
Stevens Capital Management's Adverum Biotechnologies position peaked at $87K in Q3 2015.
65 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2017.

Based on Stevens Capital Management's 13F filing for Q4 2017, filed 13 Feb 2018.